Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Nikolakis G
  • Alpsoy E
  • Anzengruber F
  • Augustin M
  • Bechara FG
  • Becherel PA
  • Benhadou F
  • Bettoli V
  • Cabete J
  • Caposiena Caro RD
  • Di Cesare A
  • Damiani G
  • Dini V
  • Giamarellos-Bourboulis EJ
  • Gáspár K
  • Glasenhardt K
  • Guillem P
  • Hafner A
  • Horvath B
  • Ingram JR
  • Jarienè V
  • Jemec GBE
  • Katoulis A
  • Kirsten N
  • Kokolakis G
  • Krajewski PK
  • Liakou AI
  • Manzo Margiotta F
  • Marzano AV
  • Matusiak L
  • Mintoff D
  • Molina Leyva A
  • Pinter A
  • Pirogova A
  • Podda M
  • Prignano F
  • Romani J
  • Romanelli M
  • Rosi E
  • Sahin S
  • Saunte DML
  • Schneider-Burrus S
  • Suppa M
  • Szepietowski J
  • Szegedi A
  • Thomsen SF
  • Tzellos T
  • Trigoni A
  • Van Der Zee HH
  • Van Straalen K
  • Valiukeviciene S
  • Vilarrasa E
  • von Stebut E
  • Zouboulis CC

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with significant diagnostic delays and impact on quality of life. Current guidelines prioritize antibiotics as first-line therapy, but experts increasingly recognize the need for earlier targeted therapy intervention to prevent irreversible scarring and tunnel formation. To establish consensus on clinical scenarios during the 14th European Hidradenitis Suppurativa Foundation Conference in February 2025, 54 HS experts participated in a Delphi consensus, using a Likert scale (-5 to +5) to vote on 16 statements concerning first-line therapy criteria with biologics and/or small molecules for eligible patients. Seventy-eight HS experts were invited, and 54 participated via hybrid onsite and electronic voting. Experts rated 16 pre-defined statements regarding first-line use of biologics and/or small molecules for HS using a Likert scale (-5 to +5). Agreement metrics were stratified as majority agreement (=70%, median 3.0-3.5), consensus (=75%, median 3.5-4.5), and strong consensus (=90%, median =4.5). Statements were subsequently ranked for clinical relevance. Strong consensus was reached for patients contraindicated for antibiotics, rapid disease progressors and those with severe disease. Consensus also supported upgrading patients with moderate disease (IHS4 = 4), frequent flares (=3 in 12 weeks), multiple affected areas and specific phenotypes including anogenital involvement. Strong consensus emerged for syndromic HS and for patients with inflammatory comorbidities such as inflammatory bowel disease and arthritis. Paediatric patients with a positive family history and moderate disease were also considered candidates for first-line biologics or small molecules. This consensus provides evidence-based criteria for upgrading HS patients to first-line biologic therapy, reflecting expert practices across Europe aimed at preventing irreversible disease progression. The results support a 'hit hard and early' approach to minimize scarring and tunnel formation, although prospective studies are still needed to validate these expert-driven recommendations.

© 2026 The Author(s). Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Datos de la publicación

ISSN/ISSNe:
0926-9959, 1468-3083

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY  WILEY

Tipo:
Article
Páginas:
-
PubMed:
41580305
Factor de Impacto:
1,613 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 8

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • JAK inhibitors; adalimumab; bimekizumab; biologics; hidradenitis suppurativa; povorcitinib; secukinumab; upadacitinib

Cita

Compartir